Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1562 clinical trials
Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. …

  • 0 views
  • 09 May, 2022
  • 1 location
Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

-cell acute lymphoblastic leukemia. At least 18 subjects will be enrolled. After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and

  • 0 views
  • 16 May, 2022
  • 1 location
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

combining the CIML NK cells with DLI approach will significantly enhance the graft versus leukemia and therefore potentially provide potentially curative therapy for these patients with otherwise extremely

  • 24 views
  • 14 Jun, 2022
  • 1 location
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

  • 0 views
  • 09 Jul, 2022
  • 1 location
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Lymphoma (B-ALL)

The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it is at treating B-ALL.

  • 0 views
  • 27 Jul, 2022
  • 1 location
  • 0 views
  • 17 Feb, 2021
  • 2 locations
  • 0 views
  • 24 Mar, 2022
  • 1 location
Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell ALL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

  • 0 views
  • 30 May, 2022
  • 1 location
  • 0 views
  • 30 May, 2022
  • 1 location
  • 0 views
  • 03 Jun, 2022
  • 1 location